Daniel Catenacci
Internal Medicine · Chicago, ILNPI 1467609537
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.4%. Reporting peaked in 2021 at $80,225 and has fallen 97.3% since, to $2,177 in 2022. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $1364.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$38K
- Lilly USA, LLC$35K
- Daiichi Sankyo Inc.$14K
- E.r. Squibb & Sons, L.L.C.$11K
- Genentech USA, Inc.$10K
- Eli Lilly$9K
- plus $45K from 12 others
Across 339 payments — averaging $9822.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.4M
- Seagen Inc.$507K
- Astrazeneca UK Limited$365K
- Incyte Corporation$304K
- E.r. Squibb & Sons, L.L.C.$188K
- AstraZeneca$173K
- plus $374K from 8 others
What the payments were for
- Consulting fees$94,93659%
- Speaking & faculty fees$60,06037%
- Travel & lodging$4,2623%
- Food & beverage$1,7851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 29 | $37,678 |
| Lilly USA, LLC | 29 | $34,712 |
| Daiichi Sankyo Inc. | 16 | $13,877 |
| E.r. Squibb & Sons, L.L.C. | 6 | $11,175 |
| Genentech USA, Inc. | 6 | $9,657 |
| Eli Lilly | 4 | $9,113 |
| AstraZeneca | 4 | $8,103 |
| Seagen Inc. | 9 | $7,185 |
| Novartis | 2 | $7,074 |
| F. Hoffmann-la Roche AG | 3 | $5,870 |
| Astrazeneca UK Limited | 1 | $4,110 |
| Incyte Corporation | 2 | $3,254 |
| Astellas Pharma US Inc | 1 | $2,668 |
| Roche Diagnostics International Ltd | 1 | $2,475 |
| Servier Pharmaceuticals LLC | 2 | $1,971 |
| Blueprint Medicines Corporation | 1 | $1,680 |
| Amgen | 1 | $325 |
| Bayer | 1 | $117 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$161,042 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Merle DiamondChicago$1.1M
- Robert KushnerChicago$516K
- Romeo UrsuaChicago$420K
- Peter O DonnellChicago$318K
- George UrbanChicago$258K
- Kristen PallokChicago$256K
- George NissanChicago$252K
- Luke LaffinChicago$162K
- Hiren ShahChicago$144K
- Toral PatelChicago$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.